Skip to content

Bispecific exposure and ternary binding

How does absorbed bispecific exposure populate binary and ternary complexes? Explore fixed regimens and bounded dose-amplitude optimization in normalized benchmark units. No clinical dose, patient prediction, global optimum, or paper-figure agreement is claimed.

Exploration notes · What are you exploring?

Notes stay on this browser.

MODEL IN MOTION 18 sec

Does higher exposure change binary and ternary binding equally?

Run settings

Run location

Explore this model

Choose a scenario, adjust inputs, and run the simulation.

Lower exposure

How does absorbed bispecific exposure populate binary and ternary complexes?

0–140 day

Scenario details

Lower exposure

How does absorbed bispecific exposure populate binary and ternary complexes?

Readouts

Ternary complex · dimensionless
Explore fixed regimens and bounded dose-amplitude optimization in normalized benchmark units. No clinical dose, patient prediction, global optimum, or paper-figure agreement is claimed.
Binary complexes · dimensionless
Explore fixed regimens and bounded dose-amplitude optimization in normalized benchmark units. No clinical dose, patient prediction, global optimum, or paper-figure agreement is claimed.
Drug exposure · dimensionless
Explore fixed regimens and bounded dose-amplitude optimization in normalized benchmark units. No clinical dose, patient prediction, global optimum, or paper-figure agreement is claimed.
Receptor a total · dimensionless
Explore fixed regimens and bounded dose-amplitude optimization in normalized benchmark units. No clinical dose, patient prediction, global optimum, or paper-figure agreement is claimed.
Receptor b total · dimensionless
Explore fixed regimens and bounded dose-amplitude optimization in normalized benchmark units. No clinical dose, patient prediction, global optimum, or paper-figure agreement is claimed.

Study purpose

  • How does absorbed bispecific exposure populate binary and ternary complexes?

Assumptions

  • Regimens and dose optimization use normalized benchmark units. Optimization does not establish a global optimum.

Inputs changed since the displayed result. Run to update the comparison.

Loading starting example…

Edit inputs

Turnover / binding

Drug elimination rate

1/day

Suggested: 0.05–0.15. You can explore beyond this range.

0.1 → —

Absorption rate

1/day

Suggested: 0.1–0.3. You can explore beyond this range.

0.2 → —

Ternary-complex internalization rate

1/day

Suggested: 0.05–0.15. You can explore beyond this range.

0.1 → —
Simulation time
day
day
140 → 168

Time between reported samples.

day
0.25 → 1

2 changes · Variation 1

Continue in the background and keep the result.

Optimize dose amplitudes

Administration times and model parameters stay fixed. Adjust starting amplitudes within the declared bounds, then compare the optimized response with the target.

Fixed-time benchmark amplitude optimization; not a clinical regimen or a paper-optimum reproduction.

Sign in to preview and run dose optimization.

Biology

How does absorbed bispecific exposure populate binary and ternary complexes?

How does absorbed bispecific exposure populate binary and ternary complexes?

Model details

20 parameters · 8 states · 8 equations · 5 derived outputs

Classification & API access
Therapeutic
generic bispecific ligand
Modality
Bispecific antibody / T-cell engager
Target
generic binding partner A, generic binding partner B
Disease / scope
Mechanism-agnostic bispecific binding research
ParameterDefaultUnitDescription
Apparent distribution volumeV3—Benchmark volume ratio
K12k1201/dayk12
K21k210.031/dayk21
Absorption rate constantka0.21/dayAbsorption rate
Degradation rate akdegA0.11/daykdegA
Degradation rate bkdegB0.11/daykdegB
Elimination rate constantkel0.11/dayDrug elimination rate
Kint akintA0.051/daykintA
Ternary complex internalization ratekintAB0.11/dayTernary-complex internalization rate
Kint bkintB0.051/daykintB
KOFF1koff10.011/daykoff1
KOFF2koff20.011/daykoff2
KOFF3koff30.011/daykoff3
KOFF4koff40.011/daykoff4
KON1kon1101/daykon1
KON2kon211/daykon2
KON3kon311/daykon3
KON4kon4101/daykon4
Ksyn aksynA11/dayksynA
Ksyn bksynB101/dayksynB

Related models

Drug-stimulated biomarker turnoverDrug injury and delayed tumor loss

Feedback: helpdesk@unibiointelligence.com.

Ubi Biologics